No Data
No Data
Join BioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
BioAffinity Technologies Set for Continued Expansion in 2025
Veterans' Research Foundation Spotlights CyPath Lung's Addition to the Federal Supply Schedule
BioAffinity Technologies Files to Sell 2.72M Shares of Common Stock for Holders
Maxim Group Maintains BioAffinity Technologies(BIAF.US) With Buy Rating, Maintains Target Price $6
BioAffinity Technologies Reports Strong Q3 Growth